Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics

Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics

Geneva, Switzerland, 17 August 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the Alpha Deal Group, LLC, a buy-side advisory firm, has initiated independent research coverage on Addex Therapeutics. Their research report highlights Addex uniquely positioned technology and pipeline, and concludes that due to past events and current market inefficiencies, Addex is trading at a significant discount to its intrinsic value. 

“There is huge value in the assets of Addex which is not recognized by the market, commented Malvi Gupta, Senior Analyst at Alpha Deal Group. “Addex has been through some challenging times, but we believe they are poised to strongly rebound as it executes on its turnaround strategy.”

Alpha Deal Groups views are based on the progress Addex has made in turning the Company around following a shortfall in funding in 2013. Addex turnaround strategy is based on advancing its clinical stage programs, dipraglurant for Parkinson’s disease levodopa induced dyskinesia (PD-LID) and cervical focal dystonia, and ADX71441 for Charcot-Marie-Tooth type 1A neuropathy and addiction. In the past 12 months Addex has made significant progress in advancing its programs in collaboration with patient advocacy groups including The Michael J. Fox Foundation for Parkinson’s Research, the Dystonia Medical Research Foundation and the US Charcot-Marie-Tooth Association. Addex has also successfully collaborated with government and academic institutions to advance its preclinical programs. Furthermore, ADX71149 a second clinical stage product is being developed by partner Janssen Pharmaceuticals Inc.

“We believe this second analyst report provides useful guidance to the investment community on the Addex investment case as we execute on our strategy to unlock the value of the Addex portfolio for our shareholders.” commented Tim Dyer, CEO of Addex.”

Alpha Deal Groups initiation of coverage research report is available on the Reuters platforms, Thomson Reuters Eikon, S&P Capital IQ and FactSet, and the Addex website at under Investors/downloads or (direct link).

About Alpha Deal Group
Alpha Deal Group, LLC is a buy-side advisory, analytics and multimedia company, a truly uniquely positioned emerging growth intelligence company and a niche market player in the value creation chain of today's global equity growth markets. Alpha Deal Group assists asset managers, hedge funds, private equity groups and the C-Suite deal teams of public and private companies on idea generation and deal sourcing for alpha opportunities wherever event-driven, valuation-gapped, equity deal scenarios may exist. Request Alpha Deal Group Intelligence on For more information, please visit:

About Addex Therapeutics
Addex Therapeutics ( is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase IIa POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase IIa for PD-LID. In parallel, dipraglurant’s therapeutic use in dystonia and treatment resistant depression is being investigated. Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. Addex also has several preclinical programs including: ADX71441 (GABAB receptor PAM) which has received regulatory approval to start Phase I and is being investigated for therapeutic use in Charcot-Marie-Tooth (Type 1A) disease, alcohol use disorder and nicotine dependence; mGluR4PAM for drug abuse and dependence, Parkinson’s disease and other neurodegenerative diseases; mGluR2NAM for treatment resistant depression and cognitive deficits; mGluR7NAM for psychosomatic disorders, TrkBPAM for neurodegenerative disorders; and GLP1PAM for type 2 diabetes. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Tim Dyer
Chief Executive Officer
Addex Therapeutics
Telephone: +41 22 884 15 61
Email: PR(at)

Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.